Pyrophosphatase 1 (PPA1) is a key enzyme that catalyzes the hydrolysis of inorganic pyrophosphate (PPi) into phosphate ions (Pi), a critical reaction for driving energetically unfavorable biochemical processes. By maintaining low intracellular PPi levels, PPA1 supports essential metabolic pathways, including nucleic acid synthesis, protein modification, and lipid metabolism. It exists in both soluble and membrane-bound forms, with its activity linked to cellular energy homeostasis, bone mineralization, and mitochondrial function. Dysregulation of PPA1 has been implicated in various pathologies, such as cancer progression, metabolic disorders, and neurodegenerative diseases.
The PPA1 antibody is a widely used tool for detecting and quantifying PPA1 expression in research. Developed in hosts like rabbits or mice, it is available in monoclonal or polyclonal forms, often validated for applications such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and enzyme-linked immunosorbent assays (ELISA). Specificity is typically confirmed using knockout controls or siRNA-mediated gene silencing. Researchers employ this antibody to investigate PPA1’s role in cellular processes, disease mechanisms, and therapeutic targeting. Its reliability is crucial for studies exploring PPA1’s association with tumor metabolism, mitochondrial dysfunction, or calcium signaling. When selecting a PPA1 antibody, factors like species reactivity, post-translational modification recognition, and batch consistency are prioritized to ensure experimental reproducibility.